Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Dec 15, 2017; 9(12): 466-474
Published online Dec 15, 2017. doi: 10.4251/wjgo.v9.i12.466
Published online Dec 15, 2017. doi: 10.4251/wjgo.v9.i12.466
Table 1 Patient characteristics by categorized tumor-stroma ratio
TSR-low (n = 36) | TSR-intermediate (n = 70) | TSR-high (n = 48) | P-value1 | ||||
n | % | n | % | n | % | ||
Gender | NS | ||||||
Male | 24 | 66.7 | 44 | 62.9 | 32 | 66.7 | |
Female | 12 | 33.3 | 26 | 37.1 | 16 | 33.3 | |
Age (yr) | M 68.0 | SD 8.0 | M 67.3 | SD 10.3 | M 65.7 | SD 10.3 | NS2 |
(range 49.0-82.0 ) | (range 40.0-87.0) | (range 43.0-91.0) | |||||
Treatment | NS | ||||||
APR | 19 | 52.6 | 31 | 44.3 | 17 | 35.4 | |
LAR | 11 | 30.6 | 28 | 40.0 | 24 | 50.0 | |
Hartmann | 6 | 16.7 | 11 | 15.7 | 7 | 14.6 | |
T-status | NS | ||||||
pT1 | 1 | 2.8 | 1 | 1.4 | 4 | 8.3 | |
pT2 | 9 | 25.0 | 23 | 32.9 | 18 | 37.5 | |
pT3 | 24 | 66.7 | 43 | 61.4 | 25 | 52.1 | |
pT4 | 2 | 5.6 | 3 | 4.3 | 1 | 2.1 | |
N-status | 0.029 | ||||||
pN0 | 16 | 44.4 | 44 | 62.9 | 34 | 70.8 | |
N1 | 15 | 41.7 | 13 | 18.6 | 11 | 22.9 | |
N2 | 5 | 13.9 | 13 | 18.6 | 3 | 6.3 | |
Stage | NS | ||||||
I | 7 | 19.4 | 21 | 30.0 | 17 | 35.4 | |
II | 9 | 25.0 | 23 | 32.9 | 17 | 35.4 | |
III | 20 | 55.6 | 26 | 37.1 | 14 | 29.2 | |
Grading | NS | ||||||
Well | 0 | 0 | 1 | 1.4 | 3 | 6.3 | |
Moderate | 31 | 86.1 | 58 | 82.9 | 40 | 83.3 | |
Poor | 5 | 13.9 | 11 | 15.7 | 5 | 10.4 | |
Adjuvant treatment | 19 | 52.8 | 21 | 30.0 | 11 | 22.9 | 0.0123 |
Radiotherapy | 17 | 18 | 9 | ||||
Chemoradiotherapy | 1 | 3 | 2 | ||||
Chemotherapy | 1 | - | - |
Table 2 Cox multivariate analysis for overall survival
N0 | N+ | |||
HR | 95%CI | HR | 95%CI | |
Age | ||||
< 70 yr | 1 | Ref. | 1 | Ref. |
> 70 yr | 3.32a | 1.75-6.28 | 2.26a | 1.10-4.65 |
Grading | ||||
Poor | 1 | Ref. | 1 | Ref. |
Moderate | 1.03 | 0.43-2.49 | 0.52 | 0.25-1.10 |
Well | 0.36 | 0.04-2.99 | 0.56 | 0.06-5.31 |
Adjuvant treatment | ||||
No | 1 | Ref. | 1 | Ref. |
Yes | 0.47 | 0.06-3.50 | 0.66 | 0.27-1.60 |
TSR | ||||
TSR-high | 1 | Ref. | 1 | Ref. |
TSR-intermediate | 2.04 | 0.99-4.21 | 1.19 | 0.50-2.84 |
TSR-low | 1.43 | 0.57-3.60 | 1.04 | 0.40-2.69 |
Table 3 Cox multivariate analysis for disease free survival
N0 | N+ | |||
HR | 95%CI | HR | 95%CI | |
Age | ||||
< 70 yr | 1.00 | Ref. | 1.00 | Ref. |
> 70 yr | 0.36 | 0.13-1.01 | 0.89 | 0.36-2.22 |
pT-status | ||||
T1 | 1.00 | Ref. | 1.00 | Ref. |
T2 | 0.11 | 0.01-1.21 | 0.66 | 0.10-4.44 |
T3 | 0.85 | 0.09-7.58 | 1.51 | 0.31-7.30 |
T4 | 1.61 | 0.07-39.27 | 1 | |
Grading | ||||
Poor | 1.00 | Ref. | 1.00 | Ref. |
Moderate | 1.43 | 0.29-6.99 | 0.58 | 0.25-1.35 |
Well | 1 | 1 | ||
Adjuvant treatment | ||||
No | 1.00 | Ref. | 1.00 | Ref. |
Yes | 0.2 | 0.01-2.57 | 1.04 | 0.32-3.41 |
TSR | ||||
TSR-high | 1.00 | Ref. | 1.00 | Ref. |
TSR-intermediate | 6.41a | 1.84-22.28 | 1.31 | 0.49-3.51 |
TSR-low | 3.7 | 0.84-16.42 | 0.93 | 0.31-2.74 |
Table 4 Cox multivariate analysis for disease specific survival
N0 | N+ | |||
HR | 95%CI | HR | 95%CI | |
Age | ||||
< 70 yr | 1.00 | Ref. | 1.00 | Ref. |
> 70 yr | 0.47 | 0.16-1.40 | 1.19 | 0.53-2.67 |
pT-status | ||||
T1 | 1.00 | Ref. | 1.00 | Ref. |
T2 | 0.12 | 0.01-1.29 | 0.48 | 0.06-3.50 |
T3 | 0.69 | 0.08-6.25 | 1.29 | 0.27-6.07 |
T4 | 0.46 | 0.02-8.70 | 1 | |
Grading | ||||
Poor | 1.00 | Ref. | 1.00 | Ref. |
Moderate | 1.03 | 0.20-5.30 | 0.46 | 0.21-1.04 |
Well | 1 | 1 | ||
Adjuvant treatment | ||||
No | 1.00 | Ref. | 1.00 | Ref. |
Yes | 0.2 | 0.01-2.57 | 1.04 | 0.32-3.41 |
TSR | ||||
TSR-high | 1.00 | Ref. | 1.00 | Ref. |
TSR-intermediate | 5.27a | 1.54-18.1 | 1.60 | 0.54-4.70 |
TSR-low | 3.48 | 0.78-15.55 | 1.22 | 0.41-3.66 |
- Citation: Scheer R, Baidoshvili A, Zoidze S, Elferink MAG, Berkel AEM, Klaase JM, van Diest PJ. Tumor-stroma ratio as prognostic factor for survival in rectal adenocarcinoma: A retrospective cohort study. World J Gastrointest Oncol 2017; 9(12): 466-474
- URL: https://www.wjgnet.com/1948-5204/full/v9/i12/466.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i12.466